Related Experiment Video

Updated: Nov 24, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K

New first-line therapy for dMMR/MSI-H CRC

Diana Romero1

  • 1Nature Reviews Clinical Oncology, . nrclinonc@nature.com.

Nature Reviews. Clinical Oncology
|December 22, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

507
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.1K

Related Experiment Videos

Last Updated: Nov 24, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

507
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

322
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
322

Articles linked to this work by shared authors, journal, and citation graph.

High-Risk Vascular Remodeling in Takayasu Arteritis: Descending Aortic Multilobulated Saccular Aneurysms and Aortic Coarctation.

JACC. Case reports·2026

New Yorkers Speak Up: Community Perspectives on Improving Healthcare Experiences in New York City.

Journal of urban health : bulletin of the New York Academy of Medicine·2025

AI-based augmentation of oncology clinical trials.

Nature reviews. Clinical oncology·2026

Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

Nature reviews. Clinical oncology·2026

De-escalation trials in multiple myeloma: past, present and future.

Nature reviews. Clinical oncology·2026

Towards liquid biopsy-based analysis of antitumour immunity.

Nature reviews. Clinical oncology·2026

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Nature reviews. Clinical oncology·2026

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026

Chemical Bond-Orchestrated Energy Depletion to Augment Lung Cancer Chemo-Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Buddy Wire-Augmented Intravascular Lithotripsy in Refractory Calcified Coronary Lesions: A Five-Case Series.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.

Biomedical microdevices·2026

Conservative and surgical treatment of wrist osteoarthritis: a systematic review.

Archives of orthopaedic and trauma surgery·2026

The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.

Cancer immunology research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us